Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its robotic pill technology.
New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet’s GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN).
Get the full story at our sister site, Drug Delivery Business News.
